scholarly article | Q13442814 |
P50 | author | Antonio Lanzavecchia | Q4776729 |
Matthew B. Frieman | Q95658074 | ||
Ralph S. Baric | Q63881333 | ||
Timothy P Sheahan | Q88410103 | ||
Davide Corti | Q88540622 | ||
Eric Donaldson | Q90822619 | ||
Barry Rockx | Q92024521 | ||
P2860 | cites work | Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection | Q27488870 |
Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain | Q27654446 | ||
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants | Q28768526 | ||
Monoclonal antibodies differentially affect the interaction between the hemagglutinin of H9 influenza virus escape mutants and sialic receptors. | Q30343834 | ||
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. | Q30356663 | ||
Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody | Q33239031 | ||
Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway | Q33383237 | ||
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants | Q33780455 | ||
Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms | Q33987404 | ||
Structural studies on viral escape from antibody neutralization | Q34302612 | ||
SARS: epidemiology | Q34305467 | ||
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group | Q34358628 | ||
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor | Q34451350 | ||
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies | Q35901171 | ||
Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice | Q35914462 | ||
Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion | Q36424092 | ||
Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge | Q36498144 | ||
Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus | Q36845879 | ||
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14 | Q36856186 | ||
Infectious bronchitis virus S2 gene sequence variability may affect S1 subunit specific antibody binding | Q38317680 | ||
A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV. | Q40073664 | ||
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies | Q40437929 | ||
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. | Q42844863 | ||
Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). | Q47736945 | ||
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus | Q47957009 | ||
Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody | Q79795066 | ||
Restoration of virulence of escape mutants of H5 and H9 influenza viruses by their readaptation to mice | Q81266087 | ||
Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms | Q84549758 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | severe acute respiratory syndrome | Q103177 |
Coronaviridae | Q1134583 | ||
monoclonal antibody | Q422248 | ||
P304 | page(s) | 946-955 | |
P577 | publication date | 2010-03-01 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus | |
P478 | volume | 201 |
Q36702376 | A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence |
Q28817689 | A decade after SARS: strategies for controlling emerging coronaviruses |
Q98721217 | A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic |
Q98776197 | A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures |
Q98778482 | A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes |
Q38275790 | A structural view of coronavirus-receptor interactions |
Q90391255 | An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections |
Q96225681 | An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review |
Q26799080 | Anti-infective immunoadhesins from plants |
Q33886371 | Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques |
Q99552342 | Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition |
Q95300582 | Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody |
Q98720898 | Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding |
Q51783750 | Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform. |
Q34594139 | Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness |
Q36440258 | Escape From Monoclonal Antibody Neutralization Affects Henipavirus Fitness In Vitro and In Vivo |
Q95642362 | How did we get here? A short history of COVID-19 and other coronavirus-related epidemics |
Q34491357 | Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing |
Q40787125 | Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo |
Q40041480 | Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus |
Q33627189 | Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution |
Q24810360 | Immunogenetic mechanisms driving norovirus GII.4 antigenic variation |
Q36154930 | Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus |
Q91900087 | Monoclonal antibodies for prophylactic and therapeutic use against viral infections |
Q38078178 | Monoclonal antibodies for prophylactic and therapeutic use against viral infections. |
Q37929687 | Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential |
Q56777344 | Novel neutralizing monoclonal antibodies protect rodents against lethal filovirus challenges |
Q39614881 | Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus |
Q35865538 | Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection |
Q64118341 | Recent Aspects on the Pathogenesis Mechanism, Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections |
Q47162709 | Receptor-binding loops in alphacoronavirus adaptation and evolution |
Q35815644 | Reconstitution of the receptor-binding motif of the SARS coronavirus |
Q35009468 | Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation |
Q35612506 | SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission |
Q96030625 | SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective |
Q36710396 | SARS-like WIV1-CoV poised for human emergence |
Q64993888 | Sequential Emergence and Wide Spread of Neutralization Escape Middle East Respiratory Syndrome Coronavirus Mutants, South Korea, 2015. |
Q36736237 | Spread of Mutant Middle East Respiratory Syndrome Coronavirus with Reduced Affinity to Human CD26 during the South Korean Outbreak |
Q87973551 | Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein |
Q88974655 | Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein |
Q94452368 | The trinity of COVID-19: immunity, inflammation and intervention |
Q38044156 | Viral fitness: definitions, measurement, and current insights |
Q47253371 | Viral metagenomics, protein structure, and reverse genetics: Key strategies for investigating coronaviruses |